Vericel earned FDA approval for a supplemental Biologics License Application, which will expand the company's Maci label to include arthroscopy, according to an Aug. 26 news release.

SurGenTec earned FDA 510(k) clearance for its B-Man bone marrow aspirate kit, according to an Aug. 23 news release.

Ossium Health's OssiGraft Prime was used in its first successful case, the orthobiologic company said July 30.

Phoenix-based Full Circle Orthopedics and Sports Medicine added mVasc treatment for orthopedic healing, according to a July 24 news release.

Regenerative medicine in spine and orthopedic surgery is growing, but its exact place in the specialties hasn't been fully cemented yet.

Tallahassee (Fla.) Orthopedic Clinic has opened a new orthotics and prosthetics suite.

From product debuts to new research, here are five key developments in orthobiologics since May 6.

OssDesign's Catalyst nanosynthetic bone graft was used in its 5,000th U.S. patient, the medtech company said May 30.

New York City orthopedic surgeon Steven Struhl, MD, has completed his first procedure using Cartiheal's Agili-C implant for regenerating articular cartilage.

Michael Wolff, MD, was named the first master instructor for the Discseel procedure, a minimally invasive outpatient spine treatment.

New York City-based Hospital for Special Surgery launched a clinical trial that will evaluate the efficacy of concentrated bone marrow aspirate as an addition to ACL revision surgery.

Physicians at Carmel, N.Y.-based Somers Orthopaedic & Spine Surgery Center have performed the first autologous live stem cell knee injection. 

Hudson, Mass.-based surface coatings provider Precision Coating has tapped Eric Manojlović as its manager of orthopedic sales. 

Lenoss Medical closed an oversubscribed series A funding round of $4 million to help accelerate commercialization of its OsteoPearl spinal allograft. 

Tetrous' EnFix TAC demineralized bone fiber implants were used in their first cases, the company said May 8.

From funding to FDA clearances, here are six key developments in orthopedic regenerative medicine since March 7.

The University of California Los Angeles is part of a multi-institution research team that earned a contract of up to $33 million to develop treatments for joint regeneration for osteoarthritis.

Orthobiologics developer OssDsign has been awarded a contract with the U.S. Department of Veterans Affairs to provide products for an additional 100 VA hospitals nationwide, according to an April 29 report from Realtid.

Daniel Grande, PhD, was named president-elect of the International Cartilage Regeneration & Joint Preservation Society, according to an April 18 news release.

Regenerative therapeutics company Theradaptive has appointed Frank Vizesi, PhD, as its chief scientific officer.